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Case-control studya b s t r a c t
Objective: To investigate the association between maternal exposure to hair dyes and hair straightening
cosmetics (HDSC) during pregnancy and leukemia at an early age (<2 yr., EAL).
Methods: A multicenter hospital-based case-control study was carried out in 13 states in Brazil between
1999 and 2007. Mothers of 176 ALL (acute lymphocytic leukemia) and 55 AML (acute myeloid leukemia)
cases and 419 controls were enrolled and interviewed. Data on maternal exposure to HDSC occurring
3 months before pregnancy, during pregnancy and during breastfeeding were obtained. Data were also
gathered on paternal exposure to HDSC before pregnancy. Unconditional logistic regression was
performed and odds ratios (OR) on the association between HDSC use and EAL were obtained after
adjustment for hormonal intake during pregnancy, maternal age, education, birth weight, and the child
skin color.
Results: An adjusted OR of 1.78 (95% C.I. 1.13–2.81) was observed between maternal exposure to HDSC in
the ﬁrst trimester of pregnancy and ALL. Regarding AML, an adjusted OR of 2.43 (95% C.I. 1.13–5.22) was
found for maternal exposure to HDSC during breastfeeding. No association between maternal exposure to
HDSC during pregnancy and ALL or AML was observed in children with MLL (Mixed Lineage Leukemia)
gene rearrangement.
Conclusions: Results in this study seem to support the hypothesis that maternal exposure to HDSC during
pregnancy may be involved in the etiology of leukemia in children under 2 years of age.
 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Leukemia is the most common childhood neoplasm, corre-
sponding to about 35.8% of cancer diagnosed in children world-
wide [1]. Its etiology seems to be characterized by multiple risk
factors involving the interaction between genetic and environmen-
tal factors [2,3].
Exposure to carcinogenic substances during pregnancy can be
harmful for the fetus, because during this critical window of devel-
opment, the hematopoietic system is composed of cells in different
maturity stages and receives constant stimuli for proliferation, dif-
ferentiation, and cellular division [3]. Intrauterine exposure to sev-
eral chemical substances, such as dypirone, estrogens and other
medications [4,5], tobacco smoke [6,7], pesticides [5] and organicsolvents [8], have been associated with infant leukemia. Further-
more, studies on infant leukemia may be useful to identify relevant
environmental risk factors, considering the short latency period
between maternal chemical exposures during pregnancy and the
development of the disease [9]. In particular, the effects of mater-
nal exposure to certain chemicals, such as those present in hair
dyes and hair straightening cosmetics (HDSC), have not been ex-
plored in relation to the development of leukemia in the offspring.
There was increased interest in investigating the association be-
tween hair dyes and cancer, after their in vitromutagenicity in bac-
teria, and carcinogenicity in animal cells were reported in 1979
[10]. However, no such associations could be detected in human
adults [11,12].
In addition, genetic factors may play an important role in the
development of leukemia [5]. In this sense, several studies revealed
the importance of the Mixed Lineage Leukemia (MLL) gene in
hematopoiesis, gene regulation and development [3,5,9]. In fact,
somatic MLL gene rearrangement is a biomarker of infant acute
lymphoblastic leukemia (ALL) [3,13,14].
Considering the evidence that the fetus would be vulnerable to
different chemicals crossing the placental barrier [5,9], this study
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HDSC during pregnancy and the development of early age leuke-
mia (EAL) in their offspring.2. Methods
2.1. Study population and design
This study is part of the ‘‘Multi-Institutional Study of Infant Leu-
kemia: Contribution of Immunomolecular Markers in Distinguish-
ing Different Etiopathogenic Factors’’, which focuses on incidence
and pathogenesis of childhood leukemia (EAL) in Brazil [14]. EAL
cases were randomly selected from Brazilian regions through the
Brazilian Collaborative Study Group of Infant Leukemia (BCSGIL)
[5]. Brieﬂy, the BCSGIL is a multicentric hospital-based case-
control study centralized at the Brazilian National Cancer Institute
(Instituto Nacional do Cancer, INCA) in Rio de Janeiro, with a
network of academic medical centers and hospitals located in 13
different states in Brazil. The BCSGIL has been exploring the asso-
ciation between environmental exposures and the risk of acute
leukemia in children younger than 2 years of age. The rationale
for including children older than 12 month-old was based on the
biological evidence that fusion of somatic genes associated with
acute leukemia starts in utero [9] and, also, to prevent missing
cases with a delayed diagnosis and/or, AML cases with MLL-r older
than 12 months.
2.2. Inclusion criteria
Patients with leukemia were classiﬁed as ALL or AML according
to morphology, standard immunophenotyping and molecular biol-
ogy techniques; MLL gene rearrangement was characterized by a
cytogenetic-molecular test following a methodology previously
described [14].
Controls were selected among children in the same age range,
which were hospitalized in the same hospitals or in general hospi-
tals located in the same municipality where cases came from, and
undergoing medical treatment for other non-malignant diseases
[13,14]. Controls were recruited among children with life-threat-
ening conditions such as infectious and parasitic diseases (33.6%),
hematological diseases (13.4%), respiratory diseases (11.7%), con-
genital anomalies (11.2%), diseases of the digestive tract (10.5%),
cardiovascular diseases (6.7%), and other hospitalization causes
(12.9%). It is acknowledged in the literature that children relatives
with life threatening conditions use to recall illness antecedents in
more detail than those of healthy children, thus restraining the
introduction of recall bias. Participation of invited cases and con-
trols in the study was, respectively, 96% and 95% [5].
2.3. Exclusion criteria
Cases and controls exclusion criteria were: (1) if children had
adoptive parents, unknown or untraced biological parents; (2) chil-
dren with diagnosis of myelodysplastic syndrome or any congeni-
tal syndromes; (3) patients with inconclusive diagnosis of any
malignant disease; and ﬁnally, patients diagnosed with other
malignant tumors were also excluded of both case and control
groups.
2.4. Data collection
Information about environmental exposures potentially associ-
ated with the leukemogenesis process was collected through a spe-
ciﬁcally designed and standardized survey. Face-to-face interviews
were conducted with the mothers of the cases and controls in or-der to obtain information on the socioeconomic background of
the family, the parents’ occupational history, and the lifestyle
and family health history. Thus, information was collected on
parental exposure to different chemical agents from the precon-
ception period to lactation, including HDSC use.
Self-reported skin color was stratiﬁed as white and non-white.
Maternal education was stratiﬁed as low (8 schooling years or low-
er), or high (>8 schooling years). Maternal age at birth was strati-
ﬁed according to the literature, and participants recruitment in
each region was performed according to local amount of EAL
diagnosis.
The variables examined in the present study are those related to
maternal HDSC use during the following periods: (i) the three-
month interval before pregnancy (preconception period), (ii) preg-
nancy (1st, 2nd, and 3rd trimesters), and (iii) the three-month per-
iod after birth (breastfeeding). HDSC use in each period was
categorized as ‘‘never’’, ‘‘occasional’’ (whether the mother reported
<2 times), ‘‘regular’’ (2 times or more) and ever (indicating any
HDSC exposure) in the aforementioned periods. Paternal hair dyes
use refers to any lifetime exposure reported. Whenever HDSC use
was mentioned, the commercial brand names were obtained, the
respective chemical components further searched and identiﬁed.
These substances were classiﬁed according to their chemical struc-
ture (www.pubchem.com) as acids, alcohols, aldehydes, amines,
ketones, chlorides, esters, phenols, inorganic substances, and other
compounds. Whenever a compound presented multiple functional
groups, it was classiﬁed according to the predominant one. Then,
the effects of the exposure to these chemicals were analyzed using
the speciﬁc commercialized brands. The commercial names of hair
cosmetics regularly commercialized were replaced by alphabet
letters (‘‘A’’, ‘‘B’’, ‘‘C’’) whenever risk estimates on the association
between their consumption during pregnancy and EAL in the
offspring were presented.
2.5. Statistical analysis
The distribution of frequencies of the studied variables among
cases and controls was ascertained using the qui-square test and
the Fisher’s exact test (two-sided).
After analysis of the studied variables distribution, crude odds
ratios exploring their association with EAL were obtained. The vari-
ables showing an association with a p-value 60.25 were selected
for further multivariate modeling with unconditional logistic
regression. Then, the variables either showing a p-value 60.25, or
those presenting at least a ten percent change on the odds ratio
magnitude following their exclusion from the model, were consid-
ered as possible confounders and thus retained in the model. Final-
ly, odds ratios (OR) and their respective 95% conﬁdence intervals
were obtained through non-conditional logistic regression models
(Statistical Package for Social Science, SPSS 15.1 software) after
adjustment for selected confounders such as maternal age and
education, child skin color, birth weight, oral contraceptives use
and pesticides exposure during pregnancy [2,5].
Odds ratios exploring the association between HDSC exposure
and EAL were also obtained comparing cases with MLL gene rear-
rangement and controls, adjusted by the aforementioned variables.
Socioeconomic level/income [15], explored in our study towards
the use of the surrogate variable maternal education, maternal
age [16], and race/ethnicity [17], have been reported in the litera-
ture as possible risk factors to childhood leukemia.
2.6. Ethical Aspects
This investigation was approved by the Ethics Research
Committee of the National Cancer Institute (CEP-INCA, 005/06)
and the Ethics Research Committee of the National School of Public
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formed signed consent was obtained from mothers of all enrolled
participants (cases and controls).3. Results
The demographic characteristics of the study participants is
shown at Table 1. All participants’ enrolment started in January
1999 and ended in December 2007. There were 650 individuals,
being 231 cases, of which 176 (76.2%) ALL, and 55 (23.8%) AML,
and 419 controls. There were no differences in the geographical
distribution of participants, although a higher proportion of white
children was observed among cases (64.5%) than controls (36.7%),
p = 0.001. Mothers of cases showed more schooling years than
mothers of controls (p = 0.001). Maternal HDSC use during
pregnancy was reported by 374 mothers (57.5%) with similar
distribution among cases (58.4%) and controls (57.0%). Regarding
paternal HSDC use before participants’ birth, a positive report
was obtained from fathers of 16 (6.9%) cases and 22 controls
(5.3%). A total of 126 chemical substances could be traced in the
HDSC reported by all participants (Pannel 1).
The analysis of selected commercial brands reported at the
interviews revealed the following risk estimates: the commercial
brand ‘‘A’’, including 2-amino-3-hydroxypyridine, carbomer, cetri-
monium chloride, 2-methyl-5-hydroxyethylaminophenol, ethanol-
amine, buthylparaben/ethylparaben, m-aminophenol, oleth-30
and polyquaternium-22, showed an adjusted OR = 2.76, 95% C.I.
0.93–8.20 for ALL (10 cases); the commercial brand ‘‘B’’, including
citronellol, linalool, propylene glycol, 2-oleamido-1.3-octadecane-
diol, trideceth-6, methylpropional, oleth-30, hydoxyisoheyl 3-
cyclohexene carboxaldehyde, laureth-3, 2-methyl-5-hydroxyethyl-
aminophenol, ethanolamine, 2-amino-3-hydroxypyridine, cetri-
monium chloride, chlorhexidine dihydrochloride, hexadimethrine
chloride, m-aminophenol, p-aminophenol, butylphenyl, sodium
stannate, carbomer, alpha-isomethyl ionone, hydroxypropyltrimo-
nium, polyquaternium-22 and tetrasodium pyrophosphate,
showed a high risk estimate for AML, with an adjusted OR = 12.5,
95% C.I. 1.44–108.4 (4 cases); the commercial brand ‘‘C’’, including
cetrimonium chloride, cetyl esters, chlorhexidine dihydrochloride,
ethanolamine, hexadimethrine chloride, lauric acid, m-aminophe-
nol, oleth-30, pentasodium pentetate, polyquaternium-22, propyl-Table 1
Sociodemographic variables distribution, leukemia cases and controls, children <2 yr.,
Brazil, 1999–2007.
Cases (n = 231) n (%) Controls (n = 419) n (%) p-value
Sex
Male 124 (53.7) 227 (54.2) 0.903
Female 107 (46.3) 192 (45.8)
Skin color
White 149 (64.5) 154 (36.7) 0.001
Non-white 77 (33.3) 251 (59.9)
Maternal age at birth (yr.)
<19 13 (5.6) 77 (18.4) 0.001
19–24 80 (34.6) 162 (38.7)
25–30 66 (28.6) 102 (24.3)
31–36 52 (22.5) 55 (13.1)
>36 20 (8.7) 23 (5.5)
Maternal education (yr.)
<9 125 (54.1) 286 (68.3) 0.001
9 or more 106 (45.9) 133 (31.7)
Geographic region
Northeast 52 (22.5) 103 (24.6) 0.911
Midwest 17 (7.4) 32 (7.6)
Southeast 134 (58.0) 231 (55.2)
South 28 (12.1) 53 (12.6)ene glycol and trideceth-6, showed an adjusted risk estimate for
ALL, OR = 4.29, 95% C.I. 0.57–3.21 (4 cases).
The ALL risk estimate associated with any maternal use of HDSC
during the ﬁrst trimester of pregnancy revealed an adjusted
OR = 1.78, 95% C.I. 1.13–2.81. An adjusted OR = 2.29, 95% C.I.
1.30–4.04 was also observed for those reporting occasional use of
these cosmetics in the same period. For AML cases, an adjusted
OR = 2.43, 95% C.I.1.13–5.22 was observed among women report-
ing HDSC use during breastfeeding, and an adjusted OR = 2.59
(95% C.I. 1.01–6.70) for occasional use in the same period (Table 2).
No association was found between HDSC exposure during preg-
nancy and MLLr (Table 3).4. Discussion
The causal association between the exposure to certain chemi-
cals and cancer has been explored and documented throughout the
literature [2,9,18]. The International Agency for Cancer Research
(IARC) has classiﬁed many chemical compounds, such as benzene
and dyes metabolized to benzidine as carcinogens to humans
(Group 1) [19]. Since the sixties hair dyes and hair cosmetics have
gained growing interest due to their potential role on carcinogen-
esis. Chemical compounds of hair dyes can be absorbed by inhala-
tion and/or skin contact causing skin and respiratory tract long
term injuries, or even cancer [20,21]. These substances may cause
accumulation of alterations in genes regulating cell differentiation,
proliferation, DNA-repair and apoptosis. These changes may lead to
the acquisition of a malignant phenotype, thus resulting in cells
immortalization, and in consequence ceasing to perform their
normal functions in the organism [19]. The association between
hair dyes exposure and cancer is controversial, despite existing
some evidence supporting the association with the development
of hematological neoplasia [21–25]. From a public health perspec-
tive, such exposure deserves special attention considering the
extensive use of hair dyes by the adult population worldwide,
which could result in a high attributable risk for this exposure.
All studies exploring the association between hair cosmetics
use and cancer were performed in adults [21–26]. Studies examin-
ing the risk of cancer in the offspring of parents exposed to such
substances have not been published. However, some studies have
provided evidence on the association between infant leukemia
and exposure to other chemicals, such as dipyrone, estrogens, pes-
ticides, and organic solvents [2,5]. These investigations suggested
that leukemogenesis may be related to the fact that the developing
fetus is more vulnerable to DNA damage during the ﬁrst stages of
pregnancy, thus leading to genetic rearrangements. Results of the
present study add some evidence to this hypothesis, with an in-
crease in ALL risk estimates in the offspring of mothers who have
been exposed to HDSC during the ﬁrst trimester of pregnancy
(OR = 1.78, 95% C.I. 1.13–2.81).
Commercialized HDSC contain a large variety of chemical com-
pounds [12]. The present investigation explored the effects of
exposure to these chemicals which were identiﬁed in the different
products whose commercial names were provided by participants.
As a result, 126 chemicals were identiﬁed, allowing us to evaluate
the association of chemical mixtures with the risk of EAL. Among
them, persulphates, organic solvents acting as endocrine disrup-
tors [19], and paraben esters also having endocrine disruption
activity [27], are included. One of these compounds, butylparaben
ester, has been associated with hematological cancer, lung adeno-
carcinoma, and osteosarcoma in mice [28]. Butylparaben ester can
also interact with DNA, RNA, and proteins, inhibiting cell division
in bacteria such as Bacillus subtilis and Escherichia coli [28].
The compound 2-methyl-5-hydroxyethylaminophenol present
in HDSC has shown in vitro mutagenic effects in mammalian cells,
Table 2
Maternal exposure to hair dyes and straightening cosmetics during pregnancy, leukemia cases and controls, children <2 yr., Brazil, 1999–2007.
HDSC (pregnancy) Controls n (%) ALL n (%) ALL Crude OR (95% CI) ALL Adj. OR* (95% CI) AML n (%) AML Crude OR (95% CI) AML Adj. OR* (95% CI)
Reported
No 180 (43.0) 108 (61.4) 1.00 1.00 28 (50.9) 1.00 1.00
Yes 239 (57.0) 68 (38.6) 0.84 (0.58–1.20) 0.79 (0.54–1.16) 27 (49.1) 1.38 (0.78–2.42) 1.21 (0.64–2.30)
Pre-conception**
Never 195 (46.5) 83 (47.2) 1.00 1.00 30 (54.5) 1.00 1.00
Occasionally (<2) 121 (28.9) 55 (31.3) 1.07 (0.71–1.61) 1.10 (0.71–1.71) 9 (16.4) 0.48 (0.22–1.05) 0.65 (0.27–1.53)
Regularly (2 or more) 103 (24.6) 38 (21.6) 0.87 (0.55–1.36) 0.84 (0.52–1.37) 16 (29.1) 1.01 (0.52–1.94) 1.08 (0.51–2.28)
Ever 224 (53.5) 93 (52.9) 0.97 (0.68–1.39) 0.98 (0.67–1.44) 25 (45.5) 0.72 (0.41–1.28) 0.88 (0.46–1.66)
1st Trimester
Never 339 (80.9) 129 (73.3) 1.00 1.00 43 (78.2) 1.00 1.00
Occasionally (< 2) 41 (9.8) 30 (17.0) 1.92 (1.15–3.21) 2.29 (1.30–4.04) 5 (9.1) 0.96 (0.36–2.56) 1.32 (0.43–4.09)
Regularly (2 or more) 39 (9.3) 17 (9.7) 1.14 (0.63–2.10) 1.25 (0.65–2.41) 7 (12.7) 1.41 (0.59–3.36) 1.97 (0.73–5.38)
Ever 80 (19.1) 47 (26.7) 1.54 (1.02–2.33) 1.78 (1.13–2.81) 12 (21.8) 1.18 (0.60–2.34) 1.71 (0.77–3.82)
2nd Trimester
Never 346 (82.6) 138 (78.4) 1.00 1.00 47 (85.5) 1.00 1.00
Occasionally (<2) 35 (8.3) 23 (13.1) 1.65 (0.94–2.89) 1.88 (1.03–3.45) 3 (5.5) 0.63 (0.19–2.13) 0.81 (0.21–3.14)
Regularly (2 or more) 38 (9.1) 15 (8.5) 0.99 (0.53–1.86) 1.08 (0.55–2.14) 5 (9.0) 0.97 (0.36–2.58) 1.15 (0.38–3.48)
Ever 73 (17.4) 38 (21.6) 1.31 (0.84–2.02) 1.48 (0.92–2.40) 8 (14.5) 0.81 (0.37–1.78) 1.04 (0.42–2.56)
3rd Trimester
Never 348 (83.1) 138 (78.4) 1.00 1.00 46 (83.6) 1.00 1.00
Occasionally (<2) 36 (8.6) 23 (13.1) 1.54 (0.87–2.71) 1.73 (0.94–3.19) 4 (7.3) 0.84 (0.28–2.47) 0.89 (0.26–3.02)
Regularly (2 or more) 35 (8.3) 15 (8.5) 1.15 (0.62–2.15) 1.19 (0.61–2.32) 5 (9.1) 1.08 (0.40–2.89) 1.13 (0.37–3.47)
Ever 71 (16.9) 38 (21.6) 1.35 (0.87–2.10) 1.47 (0.91–2.37) 9 (16.4) 0.96 (0.45–2.05) 1.06 (0.44–2.52)
Breastfeeding***
Never 341 (81.4) 137 (77.8) 1.00 1.00 39 (70.9) 1.00 1.00
Occasionally (<2) 38 (9.1) 23 (13.1) 1.52 (0.87–2.64) 1.50 (0.82–2.72) 9 (16.4) 2.07 (0.93–4.60) 2.59 (1.01–6.70)
Regularly (2 or more) 40 (9.5) 16 (9.1) 1.00 (0.54–1.85) 1.15 (0.59–2.25) 7 (12.7) 1.53 (0.64–3.65) 1.99 (0.72–5.51)
Ever 78 (18.6) 39 (22.2) 1.29 (0.84–1.98) 1.38 (0.86–2.22) 16 (29.1) 1.79 (0.96–3.37) 2.43 (1.13–5.22)
HDSC – hair dyes and straightening cosmetics.
* ORs adjusted by birth weight, maternal age at birth and education, oral contraceptives and pesticides exposure during pregnancy, and child’s, skin color.
** 3 months before birth; *** 3 months after birth.
*** HDSC use in each period was categorized as ‘‘never’’, ‘‘occasional’’ (whether the mother reported < 2 times), ‘‘regular’’ (2 times or more) and ever (indicating any HDSC
exposure).
A.C. Couto et al. / Chemico-Biological Interactions 205 (2013) 46–52 49but neither mutagenic or genotoxic effects in in vivo tests, nor car-
cinogenic effects in mice and rats have been observed [29]. From
these results it was concluded that there were no reasons for con-
cern about the carcinogenic potential of this compound when used
in hair dyes [29]. In the present study, the impact of use during
pregnancy or breastfeeding of HDSC containing 2-methyl-5-
hydroxyethylaminophenol and paraben ester was investigated.
An increased risk estimate was observed for EAL associated with
maternal use of HDSC during pregnancy, mainly with the use in
the ﬁrst trimester of gestation for ALL (OR = 1.78, 95% C.I. 1.13–
2.81), and during breastfeeding for AML (OR = 2.43, 95% C.I. 1.13–
5.22). These increased risk estimates were particularly associated
with occasional HDSC use, being higher than those observed
among mothers reporting regular HDSC use. However, a dose–ef-
fect pattern according to frequency of use was not observed. Some
possible explanations can be hypothesized for these ﬁndings. At
ﬁrst, such difference can result from HDSC underreported use dur-
ing pregnancy, mainly the regular use, since it could be socially
perceived as inadequate by the mothers who could relate the use
of HDSC with adverse health effects. Mazzei and collaborators
(2010) evaluated the risk of DNA damage in individuals exposed
to homemade formaldehyde-based capillary lotion and other addi-
tives, with the result that these compounds have a mutagenic ef-
fect in dividing cells [30]. In the opinion of these and other
authors, the genotoxic risks of these homemade formulations
should be rigorously evaluated, since these products consumers
are directly exposed to genotoxic or carcinogenic chemicals
[31,32]. Whether these homemade formulations interact with
commercialized HDSC, it could partially explain the observation
of differences in risk estimates between occasional and regular
maternal, since HDSC domestic use may be underreported.
Secondly, other explanation could lie in the fact that leukemogeniceffect of exposure to these substances may not be cumulative, but
rather triggered after reaching a certain exposure threshold. An
additional explanatory hypothesis is the fact that a long-term reg-
ular use before pregnancy may have upregulated mechanisms for
stress defense, DNA repair and detoxiﬁcation, which may be an
advantage for the fetus, compared to the situation in occasional
users. Finally, it is worth to consider that the effects of early-life
exposure to chemicals may not be characterized by a monotonic
dose–response pattern, as observed in adults [33].
The biological associations found in the present study are sus-
tained by Ames and collaborators who reported that hair dye com-
ponents are mutagenic for bacteria [10]. A comprehensive
understanding of the mechanisms of action of HDSC chemical com-
pounds leading to leukemogenesis, whether occurring, still re-
mains unknown. However, it is acknowledged that the
accumulation of mutations at regulatory loci at the different stages
of differentiation, proliferation, repair and apoptosis may evolve to
carcinogenesis [19]. The analysis of leukemic clones may provide
information about the event at which the malignant transforma-
tion occurred and the types of molecular mechanisms involved [9].
The chemical substances present in hair dyes have been object
of evaluation by IARC/WHO. So far, only few of these substances,
such as formaldehyde, have been classiﬁed as carcinogenic (Group
1), some others such as propylene oxide and chloroform as possible
carcinogens (Group 2 B), and several other compounds have been
considered as presenting inadequate evidence to evaluate their
carcinogenic effects [8,20]. As a whole, the evidence provided by
epidemiological studies on the association between hair dyes
exposure and cancer is limited, taking into account either the little
increase in risk estimates or the observed methodological inconsis-
tencies [34]. Accordingly, some authors have highlighted that fur-
ther studies on this ﬁeld should consider the time window of
Table 3
Maternal exposure to hair dyes and straightening cosmetics during pregnancy, MLLr cases and controls, Brazil, 1999–2007.
HDSC (pregnancy) Controls n (%) MLLr n (%) MLLr Crude OR (95% CI) MLLr Adj. OR (95% CI)
Pre-conception**
Children 0–11 months
Never 120 (46.9) 19 (47.5) 1.00 1.00
Occasionally (<2) 75 (29.3) 12 (30.0) 1.01 (0.46–2.20) 0.97 (0.41–2.29)
Regularly(2 or more) 61 (23.8) 9 (22.5) 0.93 (0.40–2.18) 0.80 (0.32–2.03)
Ever 136 (53.1) 21 (52.5) 0.98 (0.50–1.90) 0.89 (0.43–1.83)
Children 12–23 months
Never 75 (46.0) 11 (50.0) 1.00 1.00
Occasionally (<2) 46 (28.2) 2 (9.1) 0.30 (0.06–1.40) 0.25 (0.04–1.43)
Regularly(2 or more) 42 (25.8) 9 (40.9) 1.62 (0.64–4.14) 2.21 (0.68–7.12)
Ever 88 (54.0) 11 (50.0) 0.93 (0.39–2.23) 0.98 (0.36–2.67)
1st trimester
Children 0–11 months
Never 205 (80.1) 29 (72.5) 1.00 1.00
Occasionally (< 2) 27 (10.5) 8 (20.0) 2.09 (0.87–5.05) 1.96 (0.73–5.26)
Regularly (2 or more) 24 (9.4) 3 (7.5) 0.88 (0.25–3.12) 0.50 (0.11–2.20)
Ever 51 (19.9) 11 (27.5) 1.53 (0.71–3.26) 1.22 (0.52–2.83)
Children 12–23 months
Never 134 (82.2) 18 (81.9) 1.00 1.00
Occasionally (< 2) 14 (8.6) 1 (4.5) 0.50 (0.06–4.05) 0.65 (0.06–6.80)
Regularly (2 or more) 15 (9.2) 3 (13.6) 1.41 (0.37–5.33) 3.96 (0.72–21.91)
Ever 29 (17.8) 4 (18.1) 0.97 (0.31–3.07) 1.83 (0.47–7.16)
2nd trimester
Children 0–11 months
Never 208 (81.3) 33 (82.5) 1.00 1.00
Occasionally (<2) 26 (10.2) 5 (12.5) 1.21 (0.44–3.38) 0.94 (0.28–3.11)
Regularly (2 or more) 22 (8.6) 2 (5.0) 0.57 (0.13–2.55) 0.41 (0.09–2.04)
Ever 48 (18.8) 7 (17.5) 0.92 (0.38–2.20) 0.67 (0.25–1.80)
Children 12–23 months
Never 138 (84.7) 18 (81.8) 1.00 1.00
Occasionally (< 2) 9 (5.5) 1 (4.5) 0.81 (0.10–6.73) 1.17 (0.12–11.62)
Regularly (2 or more) 16 (9.8) 3 (13.6) 1.36 (0.36–5.11) 3.43 (0.61–19.25)
Ever 25 (15.3) 4 (18.1) 1.16 (0.36–3.71) 2.23 (0.54–9.16)
3rd Trimester
Children 0–11 months
Never 209 (81.6) 32 (80.0) 1.00 1.00
Occasionally (< 2) 26 (10.2) 4 (10.0) 1.01 (0.33–3.07) 0.64 (0.18–2.29)
Regularly (2 or more) 21 (8.2) 4 (10.0) 1.24 (0.40–3.86) 0.90 (0.26–3.11)
Ever 47 (18.4) 8 (20.0) 1.11 (0.48–2.57) 0.76 (0.30–1.94)
Children 12–23 months
Never 139 (85.3) 18 (81.8) 1.00 1.00
Occasionally (< 2) 10 (6.1) 1 (4.5) 0.73 (0.09–6.04) 0.80 (0.07–8.53)
Regularly (2 or more) 14 (8.6) 3 (13.6) 1.56 (0.41–5.96) 4.00 (0.72–22.20)
Ever 24 (14.7) 4 (18.1) 1.22 (0.38–3.90) 2.06 (0.51–8.29)
Breastfeeding***
Children 0–11 months
Never 213 (83.2) 31 (77.5) 1.00 1.00
Occasionally (< 2) 20 (7.8) 5 (12.5) 1.71 (0.60–4.91) 1.29 (0.39–4.35)
Regularly (2 or more) 23 (9.0) 4 (10.0) 1.19 (0.39–3.69) 1.03 (0.29–3.61)
Ever 43 (16.8) 9 (22.5) 1.44 (0.64–3.24) 1.16 (0.46–2.90)
Children 12–23 months
Never 128 (78.5) 17 (77.3) 1.00 1.00
Occasionally (< 2) 18 (11.0) 2 (9.1) 0.79 (0.17–3.69) 0.76 (0.14–4.16)
Regularly (2 or more) 17 (10.4) 3 (13.6) 1.25 (0.33–4.71) 2.28 (0.39–13.48)
Ever 35 (21.4) 5 (22.7) 1.02 (0.35–2.93) 1.21 (0.34–4.34)
MLLr – leukemia cases with MLL gene rearrangement.
HDSC – hair dyes and hair straightening cosmetics.
⁄ORs adjusted by birth weight, maternal age at birth and education, oral contraceptives and pesticides exposure during pregnancy, and child’s, skin color.
HDSC use in each period was categorized as ‘‘never’’, ‘‘occasional’’ (whether the mother reported <2 times), ‘‘regular’’ (2 times or more) and ever (indicating any HDSC
exposure).
** 3 months before birth.
*** 3 months after birth.
50 A.C. Couto et al. / Chemico-Biological Interactions 205 (2013) 46–52exposure and the role of genetic polymorphisms metabolizing
HDSC chemicals [12].
The present study also explored the association between
HDSC use and the occurrence of MLL-r, since the latter is known
to be a somatic mutation for early ALL [9]. No association wasobserved between maternal exposure to HDSC and either ALL or
AML with MLL-r. Thus, the investigated chemical compounds
may not act in the pathways of the MLL gene, but rather
leading to modulation of other genes in hematological cells
[35].
A.C. Couto et al. / Chemico-Biological Interactions 205 (2013) 46–52 51The current investigation has some limitations. First, no infor-
mation was collected concerning the lifetime use of maternal hair
dyes, the calendar year of starting use, or whether such use was
permanent or temporary. Pearson’s correlation coefﬁcients (r) be-
tween the time windows of exposure were high during pregnancy,
i.e., r = 0.80 between ﬁrst and second trimesters, and r = 0.67 be-
tween ﬁrst trimester and breastfeeding. Because maternal HDSC
reported use seems to have occurred during the whole pregnancy
and afterwards, deﬁnition of more speciﬁc time windows of expo-
sure may be inaccurate. Thus, despite participant mothers have
been requested to inform about HDSC use during the index preg-
nancy, they may have used them for several years, and potential
toxic effects of HDSC lifetime consumption were not evaluated in
this investigation. In addition, these chemicals are also common
components of other cosmetics and personal hygiene items, which
were not evaluated in this study. On the other hand, if a recall bias
relative to HDSC past use occurred, it probably was not differential
between case and control mothers. As usually occurs in hospital-
based case-control studies, the investigation design could also
have introduced selection bias. However, since cases and controls
were recruited from the same municipalities, if not in the same
hospitals, and considering that hospital controls were recruited
among patients with several life-threatening pathologies, we be-
lieve that the occurrence of such biases may be negligible.
Strengths of this investigation include the analysis of a series of
cases of a rare disease such as EAL, and the use of a quite detailed
questionnaire on HDSC exposure during pregnancy which includes
frequency and time window of use (i.e. preconception, pregnancy
trimesters, and breastfeeding period).
To our knowledge, this is so far, the ﬁrst investigation exploring
the association between maternal HDSC use during pregnancy and
risk of EAL in the offspring. Furthermore, exposure to speciﬁc HDSC
compounds was for the ﬁrst time evaluated addressing chemicals
mixtures as they are commercialized. In this sense, this study pro-
vides some evidence on the high risk of EAL following maternal use
of HDSC containing chemical substances previously reported in the
literature as possible mutagenic or carcinogenic in animals, such as
2-methyl-5-hydroxyethylaminophenol and parabens.
As an investigation providing some evidence on the association
between selected chemical substances and EAL, these results need
to be conﬁrmed by studies in other exposed populations. In addi-
tion, in order to prevent the potential harmful effects of HDSC
use to the developing fetus, the results obtained in this study
should be communicated to the general population, particularly
to women of reproductive age and pregnant women.5. Conclusion
This study found some evidence of association between mater-
nal HDSC use during pregnancy and the development of ALL and
AML under 2 years of age. The general population, and particularly
women, should be informed on the prudent avoidance of HDSC use
during pregnancy and breastfeeding.Conﬂict of ﬁnancial interests
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